SCHEMBL4737522

SCHEMBL4737522

CC(=O)OC(=O)c1ccc(N)cc1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.69
MAPT P10636 4/20 0.57
CYP3A4 P08684 4/20 0.57
KDR P35968 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
CHRM1 P11229 1/20 0.57
TBXA2R P21731 1/20 0.57
SLC6A2 P23975 1/20 0.57
PDE4A P27815 1/20 0.57
ADRA1A P35348 1/20 0.57
SLC6A3 Q01959 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
ALDH1A1 P00352 6/20 0.56
KDM4E B2RXH2 4/20 0.56
ESR2 Q92731 1/20 0.56
PTPN1 P18031 1/20 0.56
TDP1 Q9NUW8 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1259979 0.89 GAA (0.72) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL9575221 0.86 CYP3A4 (0.56) GAAMAPTCYP3A4KDRSMN1; SMN2
Aminosalicylic Acid SCHEMBL28180521 0.84 ALDH1A1 (0.76) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL29741471 0.84 GAA (0.66) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL27642838 0.84 GAA (0.66) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL9949356 0.84 GAA (0.66) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL15872185 0.83 GAA (0.61) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL616715 0.81 GAA (1.00) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL5306078 0.81 GAA (0.63) GAAMAPTCYP3A4KDRSMN1; SMN2
SCHEMBL20594758 0.80 GAA (0.61) GAAMAPTCYP3A4KDRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5086279-A None JP disclosed
CN-106573065-A Methods for treating inflammatory bowel disease 诺格尔制药有限公司 2017-04-19 CN disclosed
WO-2008085484-A2 TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH ENTERIC COATED FORMULATIONS COMPRISING 5-AMINOSALICYLIC ACID OR 4-AMINOSALICYLIC ACID JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2008-07-17 WO disclosed
JP-H0586279-A PRODUCTION OF ANHYDRIDE-CAPPED POLYPHENYLENE ETHER BY MELT PROCESS GENERAL ELECTRIC CO <GE> 1993-04-06 JP disclosed